PolyModels Hub raises £1.1M to digitise pharmacology
Summary
Still, its mainly driven by empirical knowledge of previously successful methods and the tacit expertise of scientists, leading to prolonged timelines for launching new products to market and sometimes even failing to pass regulatory checks, costing companies millions of dollars.Developing a drug remains expensive and time-consuming. "Our vision for PolyModels Hub is to revolutionize how scientists, digital teams, and senior stakeholders collaborate to accelerate development efforts and bring breakthrough therapies to market faster than ever. said Antonio Benedetti, co-founder & CEO.The team, which brings unique chemical and software engineering expertise, has already partnered with leading pharmaceutical companies to digitally design and run in-silico simulations for new and existing medicines. Such simulations directly impact key decisions on the quality attributes of drugs, accelerating time to market and saving millions in process development costs. "Alex Alexakis, investor at Marathon Venture Capital added: The pharma industry is being revolutionised by modern technologies including AI, biotechnology, and robotics.